From the WMFC:
Lymphoma Canada is collecting data on WM patient experiences, and is seeking assistance to reach the largest possible population of WM patients. Your input is vital for process by which Canadian health agencies and provinces determine whether to fund certain treatments for WM. Read more below.
To quote Lymphoma Canada's email:
"Lymphoma Canada is preparing a submission for the Canadian Agency for Drugs and Technologies in Health (CADTH), and the Quebec equivalent INESSS (Institut national d'excellence en santé et services sociaux). This survey provides us with patient input required for the submission. CADTH uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
The drug that will soon be reviewed by CADTH/INESSS is Ibrutinib, a BTK inhibitor, as a single agent or in combination with rituximab, for the treatment of relapsed/refractory Waldenstrom's Macroglobulinemia (WM)."
You do not need to live in Canada to complete this survey. You can still participate in this survey if you are a WM patient that has not received this therapy.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
It should only take between 15-20 minutes of your time.
Thank you for your support.
|